Chemoradiotherapy with 3-weekly CDDP 80 mg/m(2) for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study

OBJECTIVE: The global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m(2) administered once every three weeks, although cisplatin 80 mg/m(2) is also widely used as an alternative treatment to reduce adverse events in Japan. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Otaki, Kohei, Takahashi, Takeshi, Tanaka, Ryoko, Saijo, Kohei, Omata, Jo, Yokoyama, Yusuke, Shodo, Ryusuke, Ueki, Yushi, Yamazaki, Keisuke, Ota, Hisayuki, Togashi, Takafumi, Takahashi, Nao, Okabe, Ryuichi, Matsuyama, Hiroshi, Horii, Arata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800777/
https://www.ncbi.nlm.nih.gov/pubmed/36589621
http://dx.doi.org/10.3389/fsurg.2022.1035349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800777/
https://www.ncbi.nlm.nih.gov/pubmed/36589621
http://dx.doi.org/10.3389/fsurg.2022.1035349

Ejemplares similares